TGFB1 and cancer: The use of gamma-secretase inhibitors N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester (GSI DAPT) to inhibit Notch signaling in carcinoma, leads to an attenuation of transforming growth factor-β (TGF-β), which in turn controls Snail1 expression, indicating a role of Notch in EMT during cancer progression [91].